new concerns about the safety of Meridia (sibutramine)

April 2002

There are new concerns about the safety of Meridia (sibutramine).

Italy is suspending sales...a consumer group in the U.S. is asking the FDA to take Meridia off the market.

All this stems from reports of serious cardiovascular effects...MIs, strokes, arrhythmias, and some deaths.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new guidelines for PREVENTING type 2 diabetes
Cardiology ACE inhibitors and angiotensin receptor blockers are especially beneficial for preventing stroke
Cardiology More patients will be taking Plavix (clopidogrel)
Cardiology continuing statins when patients are hospitalized for severe chest pain
Osteoporosis latest thinking on treating osteoporosis in postmenopausal women
Vaccines current vaccine shortages
Vaccines Lymerix is off the market
Alzheimer's Disease link between homocysteine and dementia
Diabetes metformin can lower vitamin B12 levels
Diabetes stronger warnings about Actos and heart failure
Diabetes confused about the "sugar-free" candies marketed to patients with diabetes
Obesity & Weight Loss new concerns about the safety of Meridia (sibutramine)
Obesity & Weight Loss natural weight loss products
nocebo effect
Practice Claritin will soon go OTC